Lantern Pharma Statistics
Total Valuation
Lantern Pharma has a market cap or net worth of $34.30 million. The enterprise value is $14.77 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
Earnings Date | Aug 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Lantern Pharma has 10.78 million shares outstanding. The number of shares has decreased by -0.38% in one year.
Current Share Class | 10.78M |
Shares Outstanding | 10.78M |
Shares Change (YoY) | -0.38% |
Shares Change (QoQ) | -0.88% |
Owned by Insiders (%) | 0.42% |
Owned by Institutions (%) | 11.40% |
Float | 8.19M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 2.04 |
P/TBV Ratio | 2.04 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.86, with a Debt / Equity ratio of 0.01.
Current Ratio | 4.86 |
Quick Ratio | 4.60 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -75.66% and return on invested capital (ROIC) is -50.20%.
Return on Equity (ROE) | -75.66% |
Return on Assets (ROA) | -43.68% |
Return on Invested Capital (ROIC) | -50.20% |
Return on Capital Employed (ROCE) | -126.46% |
Revenue Per Employee | n/a |
Profits Per Employee | -$828,216 |
Employee Count | 24 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.23% in the last 52 weeks. The beta is 1.54, so Lantern Pharma's price volatility has been higher than the market average.
Beta (5Y) | 1.54 |
52-Week Price Change | -35.23% |
50-Day Moving Average | 3.43 |
200-Day Moving Average | 3.67 |
Relative Strength Index (RSI) | 45.16 |
Average Volume (20 Days) | 65,092 |
Short Selling Information
The latest short interest is 266,167, so 2.47% of the outstanding shares have been sold short.
Short Interest | 266,167 |
Short Previous Month | 254,840 |
Short % of Shares Out | 2.47% |
Short % of Float | 3.25% |
Short Ratio (days to cover) | 3.96 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -21.26M |
Pretax Income | -17.75M |
Net Income | -19.88M |
EBITDA | -21.24M |
EBIT | -21.26M |
Earnings Per Share (EPS) | -$1.85 |
Full Income Statement Balance Sheet
The company has $19.72 million in cash and $194,931 in debt, giving a net cash position of $19.53 million or $1.81 per share.
Cash & Cash Equivalents | 19.72M |
Total Debt | 194,931 |
Net Cash | 19.53M |
Net Cash Per Share | $1.81 |
Equity (Book Value) | 16.78M |
Book Value Per Share | 1.56 |
Working Capital | 16.54M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$19.12 million and capital expenditures -$11,537, giving a free cash flow of -$19.13 million.
Operating Cash Flow | -19.12M |
Capital Expenditures | -11,537 |
Free Cash Flow | -19.13M |
FCF Per Share | -$1.77 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Lantern Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 0.38% |
Shareholder Yield | 0.38% |
Earnings Yield | -57.96% |
FCF Yield | -55.79% |
Analyst Forecast
The average price target for Lantern Pharma is $25.00, which is 686.16% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $25.00 |
Price Target Difference | 686.16% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | 3.61% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |